Purpose This study investigated the correlative relationship between metabolic parameters estimated from dual time point 2-deoxy-2-[ F-FDG injection and a delayed scan 2 h after the early scan. Based on an analysis of DTPFP, we estimated the standardized uptake value (SUV) of tumors from the early and delayed scans, retention index (RI) representing the percentage change between early and delayed SUV, and metabolic volume different index (MVDI) calculated using metabolic tumor volumes (MTV). Results RI max showed a multiple positive correlative relationship with stage and IPI in lesion-by-lesion analysis (p < 0.01). In the case of IPI, the high risk group exhibited higher RI max than the low risk group (p = 0.004). In the case of revised IPI, the RI max of the low risk group were significantly lower than the intermediate and high risk groups, respectively (p < 0.01). The MVDIs of the best outcome group were decreased in comparison to the moderate outcome group (p = 0.029). There was a significant negative correlative relationship between RI max and MVDI, and the inclinations for decreased MVDIs were slightly associated with increased RIs. Conclusions RI max extracted from DTPFP had a significant relationship to extranodal involvement, staging, IPI, and revised IPI. MVDI showed significant negative correlation with RI max . Further large scale studies are warranted to support and extend these preliminary results.
Introduction
Malignant lymphoma (ML) is a malignant disease that originates from cells of the lymphatic system, and includes multiple inducing factors, diverse clinical manifestations, and immunohistochemical features [1] . The National Cancer Institute reported 69,740 new cases and 19,020 deaths from nonHodgkin lymphoma (NHL) in the United States in 2013 [2] . In oriental countries, diffuse large B-cell lymphoma (DLBCL) in particular represents a considerable portion of the various types of NHLs [3] . Although there has been dramatic prognostic improvement with new treatment techniques, such as addition of rituximab (R) to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) in recent decades [4, 5] , a little DLBCL patients seldom experience benefits from the R-CHOP regimen, with or without local radiation therapy. As such, it might be important to categorize patients with ML according to a prediction algorithm of prognosis before the start, or in the early stages of disease management.
In comparison to other malignancies, there are some more prognostic prediction systems such as the International Prognostic Index (IPI) and the International Working Group ( I W G ) r e s p o n s e c r i t e r i a w i t h 2 -d e o x y -2 -[ 1 8 F ] fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/ computed tomography (PET/CT) in lymphoma [6, 7] . Among them, the IPI-related criteria of revised IPI and age-adjusted IPI, are pretreatment prognostic indices, and revised IPI is reportedly a predictive marker in patients with DLBCL [8] . These could help hematological physicians to deal with individual specific management, and aid in predicting the long-term prognosis for each patient. Of course, although there are some limitations to distinguishing high risk groups with IPI in patients with R-CHOP [9] , these prognostic standards have been accepted as initial risk stratification and basic prognosis models in ML management strategy.
Dual time point 18 F-FDG PET/CT (DTPFP) was introduced to differentiate benign disease from a malignant condition [10] . The basic mechanism of DTPFP is that with time cancer tissues increase 18 F-FDG uptake compared to the uptake of benign cells. In breast cancer, lung cancer, and head and neck cancers [11] [12] [13] , DTPFP could have more accurate diagnostic accuracy and prognosis prediction. This potential is limited by the scarcity of reports concerning DTPFP in ML [14, 15] . To our knowledge, there are no publications evaluating the connection between quantitative parameters extracted from DTPFP, including volumetric measurement, and some specific prognostic factors particular to high grade lymphoma (HGL).
The purpose of this study was to investigate the correlative relationship between the quantitative and volumetric parameters estimated from DTPFP, and the clinical tools predicting lymphoma outcome, as well as to evaluate the measured metabolic and volumetric alterations between early and delayed 18 F-FDG PET/CT in patients with HGL.
Subjects and Methods

Subjects and Treatments
Between December 2009 and December 2014, 49 patients with newly diagnosed ML underwent DTPFP at the time of initial work up, prior to curative therapy. Among them, 23 patients were not enrolled in the current study. The causes of exclusion included low grade lymphoma or HL at final diagnosis (n = 15), other synchronous malignancy (n = 2), loss of delayed 18 F-FDG PET/CT (n = 4), and different target field between early 18 F-FDG PET/CT and delayed 18 F-FDG PET/ CT (n = 2). All patients with DLBCL and mantle cell lymphoma (MCL) received systemic chemotherapy with Rituximab (375 mg/m 2 on day 1), Cyclophosphamide (750 mg/m 2 on day 1), Doxorubicin (50 mg/m 2 on day 1), Vincristine (1.4 mg/m 2 , maximum 2 mg on day 1), and Prednisolone (100 mg/day on day 1-5), every 3 weeks (according to the standard R-CHOP regimen). The chemotherapy was delivered up to three cycles and involved field radiation therapy in stage I and II DLBCL, and a total of 6-8 cycles in stage III and IV DLBCL. The patients with peripheral T cell lymphoma (PTCL) and NK-T cell lymphoma (NKTL) received chemotherapy with standard CHOP regimen every 3 weeks up to three to six cycles, as with DLBCL, according to their stage. 
Staging and Prognosis Prediction Models
All patients included in this study were classified by Ann Arbor stage, lactate dehydrogenase (LDH) level, and degree of extranodal involvement. As a pretreatment prognostic standard, IPI was applied to all patients and revised IPI was applied to all DLCBL patients. IPI and revised IPI consist of five parameters (age, performance status, LDH, extranodal involvement, and stage) and were categorized into three different grades according to the number of each IPI factors (IPI: low (0), intermediate (1, 2) and high risk (3) (4) (5) groups; revised IPI: best (0), moderate (1,2) and poorest outcome (3) (4) (5) groups) [3, 8, 9] .
Imaging Protocol of DTPFP
All
18
F-FDG PET/CT studies were conducted with Gemini GXL 6 (Philips Healthcare, Hamburg, Germany) or Gemini TF 64 PET/CT systems (Philips Healthcare, Cleveland, Ohio, USA). All patients fasted for at least 6 h prior to 18 F-FDG injection, in order to sustain serum glucose concentrations < 150 mg/dl. Patients were encouraged to receive adequate water intake or 500 ml of intravenous half-normal saline before testing. 18 F-FDG (about 3.7 MBq/body weight in kg) was injected into all patients 1 h prior to early 18 F-FDG PET/CT scanning. All patients received instruction of shallow breath and motion reduction during image acquisition. DTPFP was performed twice; the early scan ranged from mid-cranium to mid-thigh, and the delayed scan took place 120 min after the early scan. For attenuation correction and anatomic information, a low-dose CT scan was obtained in the two PET/CT systems. The CT parameters were: 50 mA; 120 kV; 4 mm slice thickness; 4 mm increment; 0.83 pitch; 0.5 sec rotation time; and a matrix size of 512 × 512. After CT scanning, emission data acquisition was performed caudocranially in the three-dimensional mode with a 144 × 144 matrix. The emission scan time at each position was 90 sec, which was the same in the early and delayed phases. The bed positions of the early and delayed scans were 7-12 and 3-11 beds, respectively. 18 F-FDG PET images were reconstructed with a threedimensional row-action maximum likelihood algorithm (3D LOR-RAMLA) at Gemini GXL 6 PET/CT, and the standard Philips time-of-flight ordered-subsets expectation maximization reconstruction (33 subsets, three iterations) at GEMINI TF 64 PET/CT, respectively.
Image Analysis
All DTPFP images were reviewed and analyzed on Intellispace portal workstations (Philips Healthcare, Amsterdam, Netherlands). The significant positive standard was a conspicuous focus of FDG uptake within lymph node that was differentiated from adjacent surrounding tissue. All included lesions were interpreted by two experienced nuclear medicine physicians (JHLee and SKPark, who are boardcertified with 10 and 12 years of PET/CT description comprehension, respectively). Lesion axial diameters of all lymph nodes and extralymphatic lesions exceeded 1.5 cm. A region of interest (ROI) was estimated in each hypermetabolic lesion, including the hottest 18 F-FDG foci in early and delayed DTPFP scan, respectively. For semi-quantitative analysis of 18 F-FDG uptake, the standardized uptake value (SUV) was analyzed based on the patient's lean body mass (estimated decay-corrected 18 F-FDG concentration within ROI/ administered dose/lean body mass). Maximum SUV (SUV max ) and mean SUV (SUV mean ) were calculated twice, in early and delayed scans, separately. The percentage change between early SUV and delayed SUV was estimated as a retention index (RI) as follows: RI = (Delayed SUV -Early SUV) × 100/Early SUV. The SUV max was applied to this formula for estimation of RI max , respectively. Metabolic tumor volumes (MTVs) were estimated with a fixed threshold set at 75% percentage of SUV max in the lesion (VOI 75) (Fig. 1) . In case adjacent VOI 75 s overlapped with each other (30/122), each VOI 75 was adjusted with a consensus drawn by two nuclear medicine physicians [16] . We calculated the percentage change between early VOI 75 and delayed VOI 75 as the metabolic volume difference index (MVDI), using the same method applied to evaluate RI. Reactive lymph nodes were excluded, and the definition of those was not differentiated from background 18 F-FDG activity regardless of size, and showed no significant change of size or metabolism after treatment.
Statistical Analyses
The total estimated quantitative data are expressed as mean ± SD, and p values of less than 0.05 were considered statistically significant. Differences in SUV max , SUV mean , and MTV between early and delayed 18 F-FDG PET/CT were evaluated by a pair 2-tailed t-test at lesion-by-lesion analysis. The correlative relationship between metabolic or volumetric parameters and clinical factors was evaluated by Pearson's rank correlation at lesion-by-lesion analysis. The statistical differences of RI, MVDI, and SUVs according to IPIs and stage were determined using one-way analysis of variance (ANOVA) with Bonferroni post hoc test. Mann Whitney U test was used to investigate the difference according to LDH and extranodal involvement. All analyses were conducted using the SPSS software package (version 21.0, SPSS Inc., USA).
Results
Patient Characteristics
In this study, 26 patients (15 men and 11 women; mean age [± SD], 57.5 ± 17.1 years) diagnosed with HGL were included, and other patient characteristics are summarized in Table 1 . The clinical stages shown in this table were classified according to Ann Arbor Stage. Among them, 12 patients had elevated LDH (cutoff value; 300 mg/dl) and 16 patients had extranodal involvement. IPI was used to categorize patients into three groups: low risk (n = 12), intermediate risk (n = 4), and high risk (n = 10). Revised IPI classification was also applied to DLBCL patients: best outcome (n = 7), moderate outcome (n = 4), and poorest outcome (n = 7). Total estimated number of hypermetabolic lesions was 122 (extranodal lesions: 19). Lesion characteristics are summarized in Table 2 . Of all lesions, only seven showed lowered SUVs of the delayed scan, with 83 lesions displaying decreased MTVs of the delayed scan, when compared to the early scan (Fig. 2) .
Relationship Between Semi-quantitative Values of DTPFP and Volumetric Parameters
In the lesion-by-lesion analysis, significant correlative connections were found between the early SUV max and delayed SUV max , between early MTV and delayed MTV, and between early SUV mean and delayed SUV mean (r = 0.970, r = 0.999, and r = 0.965; p < 0.001, respectively). Significant negative correlative relationship was evident between MVDI and RI max (r = -0.272, p = 0.002) (Fig. 3) .
Relationship Between Metabolic Parameters Derived from DTPFP and Clinical Features
In lesion-by-lesion analysis, averages of delayed SUV max and delayed SUV mean were significantly higher than early SUV max and early SUV mean (p < 0.001, both), although the average of early MTV was higher than delayed MTV, as opposed to SUVs (Table 2) . When evaluating the relationship between DTPFP parameters and IPI, revised IPI and stage, one way ANOVA with Bonferroni post hoc test was used. The high risk group exhibited higher RI max than the low risk group (p = 0.004) (Fig. 4a) . In the case of revised IPI, the RI max (Fig. 4b) of the best outcome group were significantly lower than the moderate and poor outcome groups, respectively (p = 0.003 and p < 0.001). According to Ann Arbor stage, RI max was significantly increased stepwise (p = 0.001), with the exception of stage I (Fig. 4c) . RI max in patients with extranodal involvements were significantly higher than those without extranodal involvements (Fig. 4d) (p < 0.001). There was no significant relationship between MVDIs and IPI ( Fig. 4e) (p = 0.221). However, the MVDIs of the best outcome group were decreased in comparison to the moderate outcome group (p = 0.029) in the case of revised IPI, although there is little difference between moderate and poor outcome groups (Fig. 4f) . MVDI did not show significant difference according to stage and extranodal involvement ( Fig. 4g and h) DLBCL diffuse large B cell lymphoma; PTCL peripheral T-cell lymphoma; NTCL natural killer/T-cell lymphoma; MCL mantle cell lymphoma 
Discussion
This study demonstrates that there are variable significant relationships between the metabolic parameters, such as RI derived from DTPFP, and several well-known clinical diagnostic tools used to predict the prognosis of lymphoma patients. In addition, MVDI reflecting metabolic volumetric differences between early and delayed 18 F-FDG PET/CT shows significant negative correlation with RI, and slight negative connection with revised IPI. To the best of our knowledge, only a few published reports have evaluated RI and MVDI, matching several clinical parameters, such as stage, LDH and IPI predicting overall prognosis of ML. 18 F-FDG PET/CT has played an important role in treatment response evaluation since 18 F-FDG PET/CT was applied in earnest to lymphoma in 1990 [17] . As 18 F-FDG PET/CT can demonstrate not only lesion size and attenuation change, but also specific intrinsic metabolism, it has resolved the insolubility problems of the IWG response criteria [6] , such as residual mass possibly reflecting partial response (PR) or complete response unconfirmed (CRu) in 40% of patients with aggressive NHL and over 60% of patients with HL [18, 19] . However, as the interpretation of the positive or negative qualitative standards of 18 F-FDG PET/CT might have varied with regards to each researcher, the range of the negative predictive value and positive predictive value of early 18 F-FDG PET/CT were found to be 50-100% and 44-100% [20] [21] [22] , respectively. In addition, although grades of 18 F-FDG uptake after early 18 F-FDG PET/CT could be defined according to separate studies, interobserver variability might inevitably be present. In order to overcome these demerits of qualitative assessment, quantitative analysis of 18 F-FDG PET/CT has been applied to interim monitoring, as well as the evaluation of posttreatment responses in HGL. So, the principal purpose of our study was to investigate whether the metabolic and volumetric parameters derived from DTPFP could be utilized to evaluate the relationship between these factors and clinical prognostic guidelines such as IPI in especially HGL.
Although many clinicians have tried to evaluate the role of DTPFP by comparing single 18 F-FDG PET/CT scan, there is little in the literature related to ML. In 2012, Nakayama et al. [14] reported that delayed SUV max and the gap between early and delayed SUV max showed significant potential to discriminate benign lymph nodes and ML lesions. However, RI did not show effective calibration potential, compared with other factors. Although there has continued to be a debate over DTPFP, a considerable number of published reports have mentioned the possibility of predicting diagnostic accuracy and prognosis of RI [12, 23, 24] . In many cancers, including a b Fig. 2 [11, 25] , colorectal cancer [26] , lung cancer [21, 22] , pancreatic cancer [27] , cervical cancer [28] , and pediatric tumors [29] , DTPFP has increased diagnostic sensitivity, allowed a high degree of coordination with immunohistochemical markers, distinguished between benign and malignant tumors, and increased the capacity to predict prognosis, compared to established one-time 18 F-FDG PET/CT. It does not seem that, in any specific cancer type, there is a significant potential of DTPFP to show a higher sensitivity or specificity, considering the many published reports regarding DTPFP. In addition, from the outset of this current study, it was hypothesized that with increased interval between early and delayed 18 F-FDG PET/CT, metabolic parameters extracted from DTPFP can reflect more unique cancerous features than from universally performed one time 18 F-FDG PET/CT about 60 min after F-FDG PET/CT, has been utilized to evaluate the prognosis of cancer patients, and investigate the distinction between benign and malignant tumors [30, 31] . In our opinion, RI or MVDI extracted from DTPFP could reflect or support these unique cancerous heterogeneities. It is presumed that as aggressive cancer tissue has a greater chance of containing active metabolic components reflecting an aggressive prognosis, after a period, maximal tumoral 18 F-FDG uptake of this aggressive part could be more increased than uneven mixed tumor tissue even in HGL. So, RIs might be in agreement with the grade of IPI and revised IPI. Meanwhile, MVDI was shown to be inversely correlated with RI. Decreased trend of MVDI contrary to increased RI in HGL could represent the tumor heterogeneity in a different way. Kitao et al. [32] showed that when using a similar MTV measurement method as our tumor segmentation method, delayed MTV was significantly decreased compared to early MTV (p < 0.01), which agrees with our results. This was possibly related to the feature of relative threshold method applied to MTV. It is presumed that delayed MTVs calculated with a relative threshold as 45% or 75% of SUV could be smaller than those calculated with a fixed threshold as SUV = 2.5 because most cancer tissues at delayed scan have more FDG uptake than early scan. The results obtained in recent studies suggest that there was no significant difference between the early and delayed MTV of lung cancer, in cases applying fixed threshold method or gradient-based method [32, 33] . In addition, MVDI might be one of the prognostic markers in DLBCL patients, based on a significant inverse relationship with the revised IPI grade.
This preliminary study has several limitations. First, the total number of patients was not sufficient to examine with statistical power. However, total lesions enrolled in this study were sufficient to allow a preliminary evaluation. Second, the enrolled patients did not divide effectively according to the Lugano response criteria, and showed insignificant results (not shown), because of a better prognosis of ML patients. Third, in comparison to other reports and practical purposes, our cut-off threshold of 75% SUV applied to MTV measurement might be higher than other cut-off values. This was why the application of high cut off threshold was better than other methods to effectively distinguish between neighboring lesions. To overcome these abovementioned drawbacks, further long-term studies involving a larger number of patients are required to validate the exact relationship between the multiple clinical parameters predicting prognosis and diverse metabolic parameters extracted from DTPFP in HGL.
Conclusion
RI max differed significantly according to stage, IPI, and revised IPI which is regarded as a prognostic marker of ML. Also, MVDI showed a significant inverse relationship to RI indexes and weak negative connection with revised IPI. According to this preliminary study, the metabolic parameters of RI max and MVDI could be useful imaging markers to predict patient prognosis in HGL before chemotherapy.
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